Abstract

Atherosclerosis is one of the most reported diseases worldwide, and extensive research and trials are focused on the discovery and utilizing for novel therapeutics. Nitric oxide (NO) is produced mainly by endothelial nitric oxide synthase (eNOS) and it plays a key role in regulating vascular function including systemic blood pressure and vascular inflammation in vascular endothelium. In this study hypothesized that Impressic acid (IPA), a component isolated from Acanthopanax koreanum, acts as an enhancer of eNOS activity and NO production. IPA treatment induced eNOS phosphorylation and NO production, which was correlated with eNOS phosphorylation via the activation of JNK1/2, p38 MAPK, AMPK, and CaMKII. In addition, the induction of eNOS phosphorylation by IPA was attenuated by pharmacological inhibitor of MAPKs, AMPK, and CaMKII. Finally, IPA treatment prevented the adhesion of TNF-α-induced monocytes to endothelial cells and suppressed the TNF-α-stimulated ICAM-1 expression via activation of NF-κB, while treatment with L-NAME, the NOS inhibitor, reversed the inhibitory effect of IPA on TNF-α-induced ICAM-1 expression via activation of NF-κB. Taken together, these findings show that IPA protects against TNF-α-induced vascular endothelium dysfunction through attenuation of the NF-κB pathway by activating eNOS/NO pathway in endothelial cells.

Highlights

  • Atherosclerosis represents an important health problem and is the leading cause of mortality worldwide

  • Vascular endothelial dysfunction leads to impaired nitric oxide (NO) availability, which plays a key role in systemic blood pressure and vascular inflammation [1]

  • Pharmacological inhibition of p38 and JNK1/2 significantly reduced Impressic acid (IPA)-mediated induction of eNOS and NO production while inhibitors of Akt and ERK1/2 had no effect (Figure 4C,D). These data indicate that IPA stimulates the phosphorylation of eNOS in EA.hy926 cells is independent of Akt, ERK1/2, yet p38 and JNK1/2 were necessary for eNOS activation and NO production

Read more

Summary

Introduction

Atherosclerosis represents an important health problem and is the leading cause of mortality worldwide. The vascular endothelium plays a vital role in the prevention of atherosclerosis by decreasing oxidative stress, attenuating atherosclerotic events, and preventing vascular inflammatory and adhesion cascades. Vascular endothelial dysfunction leads to impaired nitric oxide (NO) availability, which plays a key role in systemic blood pressure and vascular inflammation [1]. Decreasing NO production in endothelial cells (ECs) is considered a major promoter of atherothrombosis. The development of strategies to protect and prevent or reduce endothelial dysfunction has become important. IPwAithInccornetarosle.s eNOS Phosphorylation and NO Production in Endothelial Cells eNOS activity is regulated by the phosphorylation/dephosphorylation state of the enzyme. Phosphorylation of eNOS at Ser1177 is pivotal in regulating NO generation [21]. IPA treatment upregulated phosphorylation of eNOS-Ser1177 as early as

IPA Increases eNOS Phosphorylation and NO Production in Endothelial Cells
Discussion
Chemicals and Reagents
Cell Culture and Treatment
Measurement of Cell Cytotoxicity
Protein Extraction and Western Blotting
Quantification of NO
Transient Transfection and Luciferase Reporter Assay
Immunofluorescence Staining
Cell–Cell Adhesion Assay
Statistical Analysis
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call